Parkinson’s Disease (PD)
is a chronic, progressive neurodegenerative disease characterized by motor symptoms, particularly tremor at rest, and rigidity, and impaired movement, as well as significant non-motor symptoms (NMS), including pain and cognitive impairment.
PD NMS, mostly anxiety, dementia, psychosis, sleep disorders, pain, and depression, are causing great difficulties for patients and caregivers alike.
Cannabidiol (CBD) is a non-psychedelic cannabinoid that in the last few years become acceptable bioactive ingredient in foods, beverages, and dietary supplements.
Due to limited CBD oral bioavailability, it is recommended to consume CBD sublingually (under the tongue).
Hundreds of clinical trials are ongoing worldwide, evaluating CBD (as a single drug or in combination with THC or other drugs) effectiveness for treatment of symptoms and diseases such as pain, Schizophrenia, Autism, Crohn’s Disease, and Cancer
Clinical and pre-clinical evidence for CBD potential for treatment of PD are known for many years, but large clinical trial intended to investigate CBD effectiveness for treatment of PD have not yet been performed.
Biota develops innovative CBD filmstrips, and plan to provide clinical safety and effectiveness of the filmstrips for treatment of PD NMS.